BR112023003466A2 - Métodos e composições para modulação genética de microambientes tumorais - Google Patents

Métodos e composições para modulação genética de microambientes tumorais

Info

Publication number
BR112023003466A2
BR112023003466A2 BR112023003466A BR112023003466A BR112023003466A2 BR 112023003466 A2 BR112023003466 A2 BR 112023003466A2 BR 112023003466 A BR112023003466 A BR 112023003466A BR 112023003466 A BR112023003466 A BR 112023003466A BR 112023003466 A2 BR112023003466 A2 BR 112023003466A2
Authority
BR
Brazil
Prior art keywords
compositions
methods
tumor microenvironments
genetic modulation
inhibitor
Prior art date
Application number
BR112023003466A
Other languages
English (en)
Portuguese (pt)
Inventor
P Bissonnette Reid
M Cesario Rosemary
Goodenow Robert
Shojaei Farbod
Gillings Mireille
Original Assignee
Huyabio Int Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huyabio Int Llc filed Critical Huyabio Int Llc
Publication of BR112023003466A2 publication Critical patent/BR112023003466A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112023003466A 2020-08-25 2021-08-24 Métodos e composições para modulação genética de microambientes tumorais BR112023003466A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063070173P 2020-08-25 2020-08-25
PCT/US2021/047380 WO2022046792A2 (en) 2020-08-25 2021-08-24 Methods and compositions for genetic modulation of tumor microenvironments

Publications (1)

Publication Number Publication Date
BR112023003466A2 true BR112023003466A2 (pt) 2023-05-09

Family

ID=80355668

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023003466A BR112023003466A2 (pt) 2020-08-25 2021-08-24 Métodos e composições para modulação genética de microambientes tumorais

Country Status (10)

Country Link
US (1) US20220110924A1 (cg-RX-API-DMAC7.html)
EP (1) EP4203955A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023539246A (cg-RX-API-DMAC7.html)
KR (1) KR20230057426A (cg-RX-API-DMAC7.html)
AU (1) AU2021333655A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023003466A2 (cg-RX-API-DMAC7.html)
CA (1) CA3190514A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023002286A (cg-RX-API-DMAC7.html)
WO (1) WO2022046792A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA202302154B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4654979A1 (en) * 2023-01-25 2025-12-03 Huyabio International, LLC Methods and compositions comprising a cardio-tolerated hdac inhibitor
CN117357530A (zh) * 2023-11-07 2024-01-09 苏州大学附属儿童医院 Pde3a抑制剂在制备治疗急性髓系白血病的药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244751B2 (en) * 2003-02-14 2007-07-17 Shenzhen Chipscreen Biosciences Ltd. Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
TWI794171B (zh) * 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
TWI808055B (zh) * 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TR201900059A2 (tr) * 2018-01-05 2019-07-22 Gnt Biotech & Medicals Corp Bi̇r farmasöti̇k kombi̇nasyon ve tümör mi̇kroortaminin ve i̇mmünoterapi̇ni̇n regülasyonu i̇çi̇n yöntem

Also Published As

Publication number Publication date
EP4203955A2 (en) 2023-07-05
CA3190514A1 (en) 2022-03-03
KR20230057426A (ko) 2023-04-28
AU2021333655A9 (en) 2024-06-06
JP2023539246A (ja) 2023-09-13
ZA202302154B (en) 2023-10-25
AU2021333655A1 (en) 2023-05-04
EP4203955A4 (en) 2024-09-18
US20220110924A1 (en) 2022-04-14
WO2022046792A3 (en) 2022-04-07
MX2023002286A (es) 2023-05-16
WO2022046792A2 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
CO2025015814A2 (es) Inhibidores de kras de 2-azabiciclo [2.2.1] heptano
MX2024004444A (es) Compuestos de quinolina como inhibidores de la proteina del virus de sarcoma de rata kirsten (kras).
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
MX2024009727A (es) Terapias de combinacion.
CO2026004964A2 (es) Moduladores de kras
MX2024000357A (es) Compuestos triciclicos como inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras).
CO2021008018A2 (es) Composiciones y métodos para modular la actividad de deshidrogenasas de cadena corta
EA201892587A1 (ru) Использование глутамат-модулирующих средств вместе с иммунотерапией для лечения рака
PH12021500004A1 (en) Pd-1/pd-l1 inhibitors
PH12020551244A1 (en) Pd-1/pd-l1 inhibitors
JOP20230170A1 (ar) مثبطات cdk2 وطرق لاستخدامها
DK1590340T3 (da) Histondeacetylase-inhibitorer
MX2022008305A (es) Dosificacion de inhibidores de shp2 y metodos de tratamiento del cancer.
MX2025003821A (es) Compuestos con actividad contra tumores mutantes de kras
ATE489360T1 (de) Inhibitoren der histon-deacetylase
BR112022003584A2 (pt) Compostos de pirrolopirimidina inibidores de perk
ZA202302154B (en) Methods and compositions for genetic modulation of tumor microenvironments
MX2025003571A (es) Inhibidores de tead y metodos de uso de los mismos
MX2022010944A (es) Inhibidores del factor de iniciacion de traduccion eucariotica 4e (eif4e) y sus usos.
WO2021142448A3 (en) Tgf-beta inhibitors and use thereof
MX2023008589A (es) Compuestos moduladores de gcn2 y usos de los mismos.
JOP20250149A1 (ar) مثبطات malt1
MX2022002443A (es) Compuestos inhibidores de perk.
MX2024006684A (es) Inhibidores de hdac novedosos y uso terapéutico de estos.
WO2024026486A3 (en) Cdk2 inhibitors and methods of using the same